跳至主要内容
临床试验/NCT04920396
NCT04920396撤回不适用

Intense Regulated Pulsed Light Vs Standard of Care for the Treatment of Meibomian Gland Dysfunction

Aston University2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2021年6月8日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
入组人数
50
试验地点
2
主要终点
Tear film stability

研究概览

简要总结

This study is to evaluate the effectiveness of E>EYE intense regulated pulsed light (IRPL) treatment compared to the current standard of care using a daily warm compress

详细描述

E-Eye is a medical device that has been specifically designed for treating dry eye syndrome due to meibomian gland dysfunction (MGD). This study is a prospective, single centred, interventional, randomized study assessing the efficacy and safety of E>EYE in the management of MGD (3 applications on days 0, 15 and 45, with a follow up 1 month later) compared to daily use of a warm compress over a period of 75 days.

The study will monitor the change in symptoms and signs of dry eye at each visit.)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

盲法说明

Ocular assessment will be undertaken by a researcher masked to the participants treatment allocation

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Willing and able to provide informed consent and participate in the required study visit
  • Subjects determined to have signs and symptoms of evaporative Dry Eye disease due to MGD, defined by the following:
  • OSDI score >13 and
  • NITBUT <= 10sec

排除标准

  • No use of warm compresses, intense pulsed light therapy or other lid warming treatment in the past 6 Months
  • Patients with greater 75% meibomian gland loss
  • Presence of ocular pathology or systemic conditions other than previously diagnosed moderate or severe chronic dry eye and/or Sjogren's syndrome, that in the investigator's judgment may affect the testing for, or diagnosis of, dry eye if present
  • Use of prescribed ocular topical medication (e.g., anti-hypertensive, steroid, Cyclosporin A, antibiotic) within the last 24 hours
  • Artificial tear usage within 2 hours prior to study testing
  • Other invasive ocular diagnostic testing within 2 hours prior to study testing
  • Eye makeup present on the eye lid within 10 minutes prior to study testing

研究组 & 干预措施

IRPL

Experimental

Three treatments with IRPL (manufacturer: E-Swin, France) on days 0, 15 and 45

干预措施: E>Eye IRPL (Device)

Warm compress

Active Comparator

Daily use of a warm compress (manufacturer: The Eye Doctor, UK) with Sterileyes® twice a day for 5 minutes

干预措施: Warm compress (Device)

结局指标

主要结局

Tear film stability

时间窗: Change between baseline and day 75

Change in non-invasive assessed tear film retention time from baseline to end of trial

Symptoms of dry eye disease

时间窗: Change between baseline and day 75

Change in Ocular Surface Disease Index (OSDI) questionnaire score from baseline to end of trial

次要结局

  • Tear volume(Change between baseline and day 75)
  • Lipid layer thickness(Change between baseline and day 75)
  • Eye redness(Change between baseline and day 75)
  • Meibomian gland patency(Change between baseline and day 75)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

James Wolffsohn

Professor

Aston University

研究点 (2)

Loading locations...

相似试验